Open AccessCertolizumab pegol for treatment of severe plaque psoriasis: local experience
Author(s) -
Н. С. Руднева,
T. G. Sadunashvili,
Ya. Yu. Chumakova,
Э. В. Натарова
Publication year - 2019
Publication title -
medicinskij alfavit
Language(s) - English
Resource type - Journals
eISSN - 2949-2807
pISSN - 2078-5631
DOI - 10.33667/2078-5631-2019-2-26(401)-34-40
Subject(s) - certolizumab pegol , psoriatic arthritis , medicine , psoriasis , arthritis , dermatology , disease , adalimumab
The article represents the results of a prospective analysis of 28 patients with severe plaque psoriasis and advanced psoriatic arthritis with insufficient response to previous systemic therapy, treated with certolizumab pegol at the Tula Regional Clinical Dermatovenerologic Dispensary in years 2017–2019. Certolizumab pegol demonstrated high and sustained efficacy in improving skin disease and manifestations of psoriatic arthritis. Safety profile of certolizumab pegol was consistent with the therapeutic class.